Generic ivermectin is the nonproprietary name used for prescription oral tablets containing ivermectin as the active ingredient. In the United States, the relevant human tablet products include 3 mg and FDA-approved 6 mg strengths. The generic name does not identify a particular company, package size, National Drug Code (NDC) or dispensing pharmacy. Those details matter when comparing listings: two entries can both say “ivermectin tablets” while referring to distinct approved products, labelers or packages. The oral ivermectin product overview places these tablets within the wider human-use ivermectin category.
Stromectol is the brand name associated with the original U.S. oral ivermectin product. FDA-approved generic versions are evaluated against an appropriate reference product under the abbreviated new drug application (ANDA) process. This is a regulatory relationship, not a promise that every generic uses the same color, imprint, inactive ingredients or packaging as Stromectol. It also does not establish that a historical brand package is available to order today. Readers looking for the brand specifically can consult the Stromectol product guide before interpreting a pharmacy listing.
The practical question when comparing generic ivermectin tablets is whether the prescription and the specific human-use product offered by the pharmacy match. Strength, dosage form, route, approved application, dispensing label and pharmacist review all matter more than a photograph or a low advertised price. A person should not substitute one strength for another, choose a regimen from an online listing or use veterinary ivermectin. The sections below explain how generic approval, therapeutic equivalence, product identifiers and U.S. pharmacy substitution rules fit together without providing personal dosing advice.
The word generic describes the product’s nonproprietary drug name and, in the context of an approved generic prescription product, its regulatory relationship to a reference drug. It does not mean a tablet can be bought without a prescription, and it does not establish its manufacturer from the product name alone. A pharmacy entry can display the ingredient as ivermectin while the actual dispensed item is identified more precisely by its strength, labeled dosage form, NDC and dispensing information. A human-use oral tablet also must not be confused with ivermectin cream or lotion, which have different routes and U.S. access requirements.
For oral products, 3 mg and 6 mg describe the amount of active ingredient in each tablet. Neither number indicates the number of tablets a person should take or which strength is clinically appropriate. A prescription may address strength, quantity and instructions based on a clinical assessment. Strength-specific product identifiers, package descriptions and labeling belong in the dedicated ivermectin 3 mg tablet and ivermectin 6 mg tablet guides.
A generic product can be legitimate even if the tablet looks different from a brand-name tablet, but appearance alone cannot prove authenticity or equivalence. Color, shape, score lines and imprints must be checked against the actual product’s labeling; a generic-looking bottle or the ingredient name printed on a storefront page is not sufficient. The pharmacy should be able to identify the precise drug product it intends to dispense and explain a change from the item previously received.
U.S. generic approvals are product- and application-specific. FDA’s approval of ANDA 215922, effective January 22, 2025, covers ivermectin tablets USP in both 3 mg and 6 mg strengths. The approval letter identifies Rubicon Research Private Limited as the application holder and Advagen Pharma Ltd. as its U.S. agent. FDA determined these products to be bioequivalent and therapeutically equivalent to the corresponding Stromectol reference-listed tablets. This is a documented regulatory example, not proof of the current commercial supply of either strength.
The 6 mg portion of that approval is important because it should not be described as a currently marketed 6 mg Stromectol brand product. FDA explains that Merck’s Stromectol 6 mg tablets were no longer marketed in the United States and were listed in the discontinued section of the Orange Book; the agency also determined that their withdrawal was not for reasons of safety or effectiveness. An approved 6 mg generic and a discontinued 6 mg reference brand therefore have different marketing histories. This distinction is about product status, not an invitation to compare or select doses.
Approval records can establish that an application and strength received FDA approval, but they cannot confirm that a particular seller currently carries the product or that every company listed for 3 mg also offers 6 mg. A shopper should separately verify the actual product record and what the dispensing pharmacy can supply. For a focused comparison of the reference brand and approved generics, see Stromectol vs generic ivermectin; a pharmacy should still confirm the exact item available for a prescription.
FDA uses several related but distinct terms when evaluating generics. Pharmaceutical equivalents have the same active ingredient, dosage form, route of administration and strength and meet applicable quality standards; they can differ in certain inactive ingredients, appearance or packaging. Bioequivalence addresses whether the generic and the reference product deliver the active ingredient at comparable rates and extents under the conditions evaluated. Therapeutic equivalence is FDA’s conclusion that qualifying products can be expected to have the same clinical effect and safety profile when used under the conditions in their labeling.
The Orange Book lists approved prescription drug products and, where applicable, therapeutic-equivalence codes. For many conventional tablets, an AB rating identifies products that meet FDA’s relevant bioequivalence requirements. The rating must be interpreted within the appropriate active ingredient, dosage form, route and strength grouping; it is not a blanket statement that a 3 mg tablet and a 6 mg tablet are individually substitutable. FDA’s evaluation also does not mean every inactive ingredient, imprint or package description has to match.
Therapeutic equivalence and legal pharmacy substitution are related but not identical questions. The first is a federal regulatory evaluation; the second also depends on the actual prescription, state law and the pharmacist’s duties. A patient who sees a change in the manufacturer or tablet appearance can ask the pharmacist to identify the new product and explain whether it is an appropriate substitution for the prescription. An online description using the word generic is not a substitute for consulting an FDA drug record.
Several different company names can appear around one prescription drug product. An ANDA holder is the company associated with the approved application; a manufacturer may perform production activities; a labeler is identified in the drug-listing system; and a distributor or repackager may appear on a product package. Those roles should not be treated as synonyms. For example, FDA’s ANDA 215922 approval letter identifies Rubicon as the applicant and Advagen as its U.S. agent. That letter alone does not identify every package that a retail pharmacy may offer or establish present-day supply.
An NDC is a product and package identifier used in U.S. drug listings. It helps distinguish labeler and package records, but the existence of an NDC does not by itself demonstrate that stock is available, that a seller is licensed or that an item has the FDA approval status claimed in an advertisement. The FDA Orange Book is the better starting point for approval and therapeutic-equivalence questions; DailyMed is useful for product labeling and descriptions. A pharmacist can connect those records to the exact dispensed item when necessary.
When comparing two generic offers, request enough information to identify the actual product rather than relying on a broadly worded marketplace title. The pharmacy should be able to confirm the prescribed strength, human oral dosage form, product labeler or supplier as relevant, and the item ultimately dispensed. It is reasonable to ask about a change in labeling or appearance, but it is not sound to infer quality or therapeutic superiority simply from a different company name or lower listed price.
A useful generic comparison separates FDA-regulatory facts from details that vary by package and pharmacy. The same active ingredient can appear under several labelers or NDCs, and a brand reference can remain important for approval purposes even when a particular historic strength is discontinued. The table below identifies what each type of information answers and what it cannot prove. It does not rank manufacturers or recommend one strength over another.
For a purchase-related decision, no single entry in an online listing should stand in for this combined review. The patient’s prescription, a product’s approved strength and route, and the dispensing pharmacist’s confirmation must agree. If an online seller does not identify its licensed pharmacy or cannot explain how a prescription is validated, the seller’s generic claim should be treated cautiously.
| Check | What it establishes | What it does not establish | Best next step |
|---|---|---|---|
| Drug name and dosage form | Ivermectin as the ingredient; oral tablet rather than cream, lotion or veterinary formulation | That a specific tablet strength or regimen is right for a patient | Match the prescription to a human-use oral tablet |
| Strength: 3 mg or 6 mg | Amount of ivermectin in each individual tablet | That one strength may replace another without prescriber or pharmacist review | Check the exact prescribed strength and instructions |
| FDA ANDA or Orange Book entry | Approval identity and applicable therapeutic-equivalence information | Current pharmacy inventory or all companies marketing the strength | Confirm the relevant application and strength grouping |
| DailyMed label and product description | Published labeling, warnings and product-identification information | That an online seller has that labeled product on hand | Compare the dispensing item with its actual label |
| NDC and listed labeler | Specific drug or package listing identity | Independent confirmation of approval, seller legitimacy or available stock | Ask the pharmacy to identify the package intended for dispensing |
| Pharmacy dispensing label | Patient-specific strength, directions and dispensed product information | That a discrepancy in tablet appearance can safely be ignored | Ask the pharmacist to resolve any mismatch before use |
Generic substitution is a pharmacy and prescribing decision governed by the prescription, applicable state law and the drug products involved. A prescriber may specify a brand or otherwise restrict substitution, and the pharmacist must follow relevant requirements when selecting an equivalent approved product. The existence of an FDA generic approval does not compel a pharmacy to dispense an item it does not stock, and it does not authorize a patient to modify a prescription independently.
Substitution within an appropriate therapeutic-equivalence grouping should not be confused with switching the tablet strength. A prescription written for one strength may require a clinician or pharmacist to evaluate whether a different product presentation can fulfill it under applicable rules; a person should never recalculate the regimen from the milligram number on a listing. The dedicated ivermectin prescription guide explains general prescription validity and professional review, without treating generic substitution as a self-service product choice.
If the pharmacy offers a different generic manufacturer from a previous fill, ask what exactly is being changed: the labeler, package NDC, tablet appearance, strength or prescribed directions. Differences in packaging are not necessarily evidence of a problem, but a discrepancy should never be dismissed without checking. The pharmacist can confirm the dispensed medication and, when needed, contact the prescriber to resolve uncertainty before the patient uses the tablets.
A practical pharmacy check starts with product identity rather than a claim of the lowest cost. Ask whether the offered item is a human-use prescription oral tablet, which strength and quantity will be dispensed, and how the pharmacy identifies the product on its label. Ask whether the medicine is the branded item requested or a generic, and whether any proposed change needs prescriber authorization. The pharmacy should be able to answer questions about the drug it plans to dispense, even when a distributor’s inventory screen does not show every regulatory detail.
Other useful questions involve the next steps: is the prescription valid and ready to process, is a product available or must it be ordered, and when will the pharmacist be able to confirm fulfillment? Those are real-time questions for the particular pharmacy. A listing on a search-results page, including one for a documented generic, does not establish that the local counter or mail-order service can fill the prescription. For in-person coordination, the local ivermectin pharmacy guide covers pickup and prescription transfers.
For online offers, verify the pharmacy independently rather than assuming a recognized generic name makes the seller trustworthy. Legitimate U.S. prescription tablet dispensing requires appropriate pharmacy licensing and a valid prescription; a promise of prescription-free oral ivermectin is a warning sign, not a convenience feature. The online pharmacy verification guide addresses seller credentials and contact information in detail. Product identification and seller verification answer different questions, and both need attention.
U.S. oral ivermectin tablets are prescription drugs with labeled indications including intestinal strongyloidiasis and onchocerciasis. The indication, patient assessment and product directions are clinical matters, not characteristics that can be inferred from a generic manufacturer’s name. The strongyloidiasis overview addresses a labeled treatment context. Oral ivermectin is also prescribed off-label in some circumstances, including scabies; that does not convert scabies into an FDA-approved oral-tablet indication or guarantee that a clinician will prescribe it.
Generic approval does not remove the need to review contraindications, warnings, other medicines, pregnancy or breastfeeding considerations and patient-specific risks. A pharmacist and clinician can evaluate clinically important concerns in light of the labeled product and medical history. This page does not recommend tablet strength, treatment frequency or a course of therapy. The ivermectin safety overview covers the shared safety questions and relevant differences among the human dosage forms.
Ivermectin cream 1% for rosacea and lotion 0.5% for head lice have different dosage forms and purposes from oral tablets. Veterinary ivermectin products may have concentrations, formulations or intended uses that are inappropriate for humans; they should not be treated as a source of human generic tablets. FDA has not approved ivermectin for preventing or treating COVID-19. Pharmacy shopping information should remain separate from claims about unapproved uses or instructions for self-treatment.
The amount a person pays for generic ivermectin tablets can depend on the product and tablet strength, prescribed quantity, pharmacy, insurance benefits, deductibles and current contract terms. An old cash-price screenshot or a generic comparison headline is not a reliable quote for an individual fill. A guide to ivermectin prices explains the factors behind cash-price differences, while insurance coverage information discusses formularies and benefit checks. Neither an approval record nor a lower displayed price guarantees reimbursement or availability.
For help understanding the broader prescription-to-pharmacy process, see how to buy ivermectin through a licensed U.S. pharmacy. Generic product identification is one part of that process; prescription validation and fulfillment involve additional checks. If home delivery is offered, fulfillment still depends on the dispensing pharmacy, valid prescription, applicable rules and actual stock. Ivermectin delivery information addresses shipping and safe receipt. No delivery time, free-shipping offer or stock claim should be inferred from the word generic.
At pickup or receipt, check the pharmacy label against the prescription and confirm the strength and directions before use. If the tablets have an unexpected appearance or the package information is inconsistent, retain the labeled container and ask the pharmacy to investigate instead of guessing from an online photo. Follow the product’s labeled storage instructions and use the pharmacist as the point of contact for questions about the dispensed item. This final identity check is more reliable than a manufacturer comparison based only on a marketplace title.
Generic oral ivermectin tablets contain the active ingredient ivermectin. FDA-approved generic products are evaluated against the appropriate reference-listed product, including bioequivalence and therapeutic equivalence requirements. Products can differ in certain inactive ingredients, appearance or packaging, so the specific drug and strength should be verified.
FDA has approved generic oral ivermectin tablets in 3 mg and 6 mg strengths, including both strengths under ANDA 215922 in January 2025. Approval does not demonstrate that every manufacturer markets both strengths or that a particular pharmacy currently stocks either one.
The strengths contain different amounts of ivermectin per tablet. FDA therapeutic-equivalence conclusions apply within the relevant product and strength context; they do not authorize patients to exchange strengths or adjust tablet counts on their own. Any change must be reviewed through the prescription and dispensing process.
No. FDA approval establishes a regulatory status, not current availability at a specific pharmacy. The dispensing pharmacy must confirm which product, strength and quantity it can actually obtain for a valid prescription.
FDA Orange Book records can be used to check the approved application, dosage form, strength and relevant therapeutic-equivalence information. DailyMed helps identify published labeling, and the pharmacist can verify the product being dispensed. An NDC or online listing alone is not proof of FDA approval.
Yes. FDA-approved generics can differ in some inactive ingredients and physical characteristics. Even so, an unexpected appearance should be checked against the product label and verified by the dispensing pharmacist rather than assumed to be correct.
A pharmacy may be able to dispense an appropriately therapeutically equivalent generic when allowed by the prescription and applicable state substitution rules. Prescriber instructions and pharmacist review matter. Substitution is not an automatic authorization to change strength, dosage form or regimen.
Not necessarily. The FDA application holder, manufacturing company, labeler, distributor and repackager can have different roles. The actual dispensing package and pharmacy record are needed to establish the specific product supplied.
No. Human oral ivermectin tablets are prescription medicines in the United States. The existence of over-the-counter ivermectin lotion for head lice does not change the prescription status of oral tablets. Sellers offering oral tablets without a valid prescription raise important safety and legitimacy concerns.
Oral ivermectin tablets have FDA-labeled indications for certain parasitic worm infections. Oral use for scabies is off-label and requires clinician judgment. FDA has not approved ivermectin to prevent or treat COVID-19. A generic name or an online sales claim does not establish an appropriate treatment for an individual.